|
|
PRECAUTIONS
Primidone CAS number 125-33-7
Do not use in the following situations:
* Allergy to phenobarbital porphyria
Use with caution in the following situations:
* Kidney disease
* Liver disease
Pregnancy: Reports suggest an association between use of anticonvulsant
drugs by women with epilepsy and an increased number of birth defects in
children born to these women. Other factors (eg, genetics or the epileptic
condition) may also contribute to the higher incidence of birth defects.
Most mothers receiving anticonvulsant medication deliver normal infants. Do
not discontinue anticonvulsant drugs used to prevent major seizures. This
could result in the occurrence of seizures and oxygen deficiency in body
tissues and an increased risk to both the mother and the unborn child. In
cases where seizures do not pose a serious threat, your doctor may recommend
discontinuation of anticonvulsant's prior to and during pregnancy. It is not
known whether even minor seizures constitute some risk to the developing
embryo or fetus. Reports suggest that mother's use of anticonvulsant drugs,
particularly barbiturates, is associated with a blood clotting defect in the
newborn that may cause a bleeding problem within 24 hours of birth. It has
been suggested that vitamin K be given to the mother one month prior to and
during delivery, and to the infant, immediately after birth.
Breastfeeding: Primidone appears in breast milk. It may cause the infant to
be unusually drowsy or sleepy. Consult your doctor before you begin
breastfeeding.
Lab Tests: Lab tests may be required during treatment with primidone. Tests
may include complete blood counts, liver and kidney function tests and blood
levels of primidone.
|
©
2004 - 2009
Taj Pharmaceuticals Limited
. All rights reserved
India